Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

mTORC1/mTORC2 inhibitor Palomid 529

An orally bioavailable inhibitor of raptor-mammalian target of rapamycin (mTOR) complex 1 (mTOR complex 1; mTORC1; TOR complex 1; TORC1) and rictor-mTOR (mTOR complex 2; mTORC2; TOR complex 2; TORC2), with potential antineoplastic activity. Upon oral administration, mTORC1/mTORC2 inhibitor palomid 529 targets, selectively binds to and inhibits both mTORC1 and mTORC2, which may result in apoptosis and a decrease in proliferation in mTORC1/2-expressing tumor cells. mTOR is a serine/threonine kinase that is upregulated in some tumors; it plays an important role in the PI3K/Akt/mTOR signaling pathway which is often deregulated in cancer cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:mTOR inhibitor XL388
TORC1/TORC2 inhibitor palomid 529
Code name:P 529
P-529
P529
Palmoid 529
palomid 529
palomid 529
palomid-529
palomid529
RES 529
RES-529
RES529
SG 00529
SG-00529
SG00529
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search